Technology | March 25, 2015

FDA Clears Impella for High-Risk PCI

Impella 2.5 is the only FDA-cleared percutaneous hemodynamic support device determined to be safe and effective for the high-risk PCI indication

Impella, FDA, high risk PCI, abiomed

Abiomed's Impella 2.5 now has an FDA indication for high-risk PCI.

March 24, 2015 – The U.S. Food and Drug Administration (FDA) has granted pre-market approval (PMA) clearance for Abiomed’s Impella 2.5 heart pump during elective and urgent high-risk percutaneous coronary intervention (PCI) procedures.

This additional FDA indication is based on the extensive clinical data submitted by Abiomed to the FDA to support this PMA as part of the 515 initiative. Impella 2.5, the world’s smallest heart pump, is the first hemodynamic support device to receive a PMA indication for use during high-risk PCI procedures, demonstrating its safety and effectiveness for this complex patient population.

With this approval, the Impella 2.5 is a temporary (6 hours or less) ventricular support device indicated for use during high-risk PCI performed in elective or urgent hemodynamically stable patients with severe coronary artery disease and depressed left ventricular ejection fraction, Use is deteremined by a heart team, including a cardiac surgeon, when high-risk PCI is the appropriate therapeutic option. Use of the Impella 2.5 in these patients may prevent hemodynamic instability that may occur during planned temporary coronary occlusions and may reduce peri- and post-procedural adverse events.

The product labeling allows for the clinical decision to leave Impella 2.5 in place beyond the intended duration of less than 6 hours due to unforeseen circumstances.

Per the 2011 ACC/AHA guidelines, it is a Class 1 recommendation for a heart team, which includes a cardiac surgeon, to determine the treatment strategy for revascularization (either PCI or surgery).  This decision is made based on a pre-defined institutional protocol or on a per patient basis.  If the protocol determines that PCI is appropriate, Impella is the only hemodynamic support device proven safe and effective for high-risk PCI.  This heart team approach has also been utilized for the treatment strategy for heart valve replacement.

“The rigorous data from FDA clinical trials such as PROTECT I and PROTECT II demonstrate that complex, high-risk patients undergoing protected PCI with Impella 2.5 support experience reduced adverse events, improved quality of life and are able to return home faster with fewer repeat procedures,” said William O’Neill, M.D., Henry Ford Hospital in Detroit.  “The heart team approach has evolved into a mainstream practice recognized by the guidelines for determining the need for PCI versus surgery and will continue to act as a platform for the screening and determination of the appropriate revascularization treatment for this high risk patient population.”

Trial Data
In addition to the U.S. clinical trial data, the Impella 2.5 PMA submission included clinical and scientific supporting evidence from more than 215 publications, totaling 1,638 Impella 2.5 patients and incorporated a medical device reporting (MDR) analysis from 13,981 Impella 2.5 patients.  

In addition to PROTECT I and PROTECT II, further data was provided in the submission from 637 high-risk patients enrolled in the U.S. Impella registry.  The U.S. registry is an ongoing multicenter, observational retrospective registry including 49 centers.  The data collection from the registry includes Institutional Review Board (IRB) approval, complete data monitoring and Clinical Events Committee adjudication. PMA analysis included hemodynamic science described in the literature and validated with a series of pre-clinical and clinical studies.

“As heart disease patients get sicker, more complex, and desire minimally invasive solutions, there are few options available to them to help improve their quality of life in a cost effective manner,” said Michael Minogue, chairman, president and chief executive officer, Abiomed.  “We are excited that Impella has been recognized as a device that can potentially become the new standard of care with a ‘first of its kind’ approval.”

The Impella System

The Impella 2.5 received 510(k) clearance from the FDA in 2008, is supported by clinical guidelines and has been reimbursed by the Centers for Medicare and Medicaid Services (CMS) under ICD-9-CM code 37.68 since 2008 for multiple indications, including high-risk PCI.  The Impella product portfolio, which also includes the Impella CP, Impella RP and Impella 5.0, has supported more than 25,000 patients in the United States. 

Per the regulatory process, Abiomed will conduct a single arm, post approval study on the Impella 2.5, collecting data on high-risk PCI patients.  The Impella CP and Impella 5.0 will be submitted in the future as PMA supplements and will retain their 510(k) clearances until completion of the FDA process.  The Impella RP device received Humanitarian Device Exemption (HDE) approval in January 2015.  For the Impella RP Launch, the hospital heart team will be hosted at company headquarters for a rigorous certification process followed by on-site training at their hospital.

Watch a VIDEO demonstration of how the Impella works.

For more information: www.abiomed.com

Related Content

Tryton Side Branch Stent Recognized With Premier Technology Breakthrough Award
News | Stents Bifurcation| September 21, 2017
September 21, 2017 — Cardinal Health and Tryton Medical Inc.
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Corindus Announces First Patient Enrolled in PRECISION GRX Registry
News | Robotic Systems| September 18, 2017
September 18, 2017 — Corindus Vascular Robotics Inc.
Two-Year ILLUMENATE Trial Data Demonstrate Efficacy of Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons| September 18, 2017
Philips announced the two-year results from the ILLUMENATE European randomized clinical trial (EU RCT) demonstrating...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Peter Schneider, M.D. presents late breaking clinical trial results at VIVA 17 in Las Vegas. Panelists (l to r) Krishna Rocha-Singh, M.D., Sean Lyden, M.D., John Kaufman, M.D., Donna Buckley, M.D.

Feature | Cath Lab| September 14, 2017
September 14, 2017 — Here are quick summaries for all the key late-breaking vascular and endovascular clinical trials
Mississippi Surgical and Vascular Center Uses Toshiba Ultimax-i FPD to Save Patients' Limbs
News | Angiography| September 14, 2017
The southern U.S. sees some of the highest numbers of chronic medical conditions, such as peripheral artery disease...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Philips Showcases Integrated Vascular Solutions at VIVA 2017
News | Peripheral Artery Disease (PAD)| September 13, 2017
Philips announced its presence at the Vascular Interventional Advances (VIVA 17) Annual Conference in Las Vegas from...
Overlay Init